LEDERMAN SETH 4

What Happened

• Seth Lederman, CEO of Tonix Pharmaceuticals (TNXP), was granted two derivative awards on Feb 24, 2026 totaling 269,007 shares (134,504 and 134,503). The filing reports an acquisition price of $0.00 for each award; the awards are listed as derivative securities (options) rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (timely within the usual 2-business-day window).
• Award amounts: 134,504 shares and 134,503 shares, total = 269,007 shares.
• Reported price: $0.00 (derivative awards). The filing excerpt does not specify an exercise (strike) price or immediate cash value.
• Post-transaction ownership: Not disclosed in the provided excerpt.
• Footnotes: F1 — one-third of the option vests on the first anniversary of issuance and then 1/48th each month thereafter for 36 months; F2 — granted under the Issuer’s Amended and Restated 2020 Stock Incentive Plan.

Context

• These entries are awards of derivative securities (options) as part of executive compensation—not open-market buys or sales. Vesting conditions mean the awards are subject to time-based restrictions before they can be exercised or sold. The filing does not indicate any immediate exercise or sale of shares.